[Biological agents and tofacitinib in rheumatoid arthritis]

Gonzalez L, López A, Secco A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A
Record ID 32017000286
Authors' recommendations: High-quality evidence shows that adalimumab, etanercept, infliximab, certolizumab, golimumab, abatacept, tocilizumab, rituximab and tofacitinib, are effective in controlling rheumatoid arthritis activity and improving the physical function of those patients with active disease and inadequate response or intolerance to standard disease-modifying drugs. There is no clear evidence that any of these drugs is better than the other. Most of the clinical practice guidelines recommend its indication in patients with moderate to severe active disease, who have failed or are intolerant to one or more standard drugs and for some of them, when there is inadequate response to a first biological agent. The health sponsors surveyed cover all or most of these therapies in these groups of patients.
Project Status: Completed
Year Published: 2017
URL for published report: www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Arthritis, Rheumatoid
  • Biological Factors
  • Humans
  • Piperidines
  • Pyrimidines
  • Pyrroles
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.